EyePoint Pharmaceuticals(EYPT) - 2025 Q1 - Quarterly Results

Exhibit 99.1 EyePoint Reports First Quarter 2025 Financial Results and Highlights Recent Corporate Developments – Enrollment continues to exceed expectations in DURAVYU™ Phase 3 wet AMD clinical trials with over 90% of patients randomized into the LUGANO trial and over 50% into the LUCIA trial, reinforcing confidence in enrollment completion in 2H 2025 and expected first-to-market advantage – – $318 million of cash, cash equivalents and marketable securities as of March 31, 2025, provides cash runway into 2 ...